JP2024515646A5 - - Google Patents

Info

Publication number
JP2024515646A5
JP2024515646A5 JP2023563176A JP2023563176A JP2024515646A5 JP 2024515646 A5 JP2024515646 A5 JP 2024515646A5 JP 2023563176 A JP2023563176 A JP 2023563176A JP 2023563176 A JP2023563176 A JP 2023563176A JP 2024515646 A5 JP2024515646 A5 JP 2024515646A5
Authority
JP
Japan
Prior art keywords
hla
cells
magec2
peptide
optionally
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023563176A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024515646A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/024728 external-priority patent/WO2022221479A2/en
Publication of JP2024515646A publication Critical patent/JP2024515646A/ja
Publication of JP2024515646A5 publication Critical patent/JP2024515646A5/ja
Pending legal-status Critical Current

Links

JP2023563176A 2021-04-14 2022-04-14 Ｍａｇｅｃ２免疫原性ペプチド、ｍａｇｅｃ２免疫原性ペプチドを認識する結合性タンパク質、及びその使用 Pending JP2024515646A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163174808P 2021-04-14 2021-04-14
US63/174,808 2021-04-14
US202263329523P 2022-04-11 2022-04-11
US63/329,523 2022-04-11
PCT/US2022/024728 WO2022221479A2 (en) 2021-04-14 2022-04-14 Magec2 immunogenic peptides, binding proteins recognizing magec2 immunogenic peptides, and uses thereof

Publications (2)

Publication Number Publication Date
JP2024515646A JP2024515646A (ja) 2024-04-10
JP2024515646A5 true JP2024515646A5 (enExample) 2025-04-21

Family

ID=83641016

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023563176A Pending JP2024515646A (ja) 2021-04-14 2022-04-14 Ｍａｇｅｃ２免疫原性ペプチド、ｍａｇｅｃ２免疫原性ペプチドを認識する結合性タンパク質、及びその使用

Country Status (11)

Country Link
US (1) US20240190931A1 (enExample)
EP (1) EP4323379A4 (enExample)
JP (1) JP2024515646A (enExample)
KR (1) KR20240007162A (enExample)
AU (1) AU2022256469A1 (enExample)
BR (1) BR112023021162A2 (enExample)
CA (1) CA3216553A1 (enExample)
IL (1) IL307601A (enExample)
MX (1) MX2023012141A (enExample)
TW (1) TW202304964A (enExample)
WO (1) WO2022221479A2 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117820429B (zh) * 2024-01-11 2024-06-18 中国水产科学研究院南海水产研究所 一种具有inos抑制作用的乌鳢源活性肽
TW202547854A (zh) * 2024-04-08 2025-12-16 美商帝斯肯醫療公司 Ｍａｇｅｃ２免疫原性肽、識別ｍａｇｅｃ２免疫原性肽之結合蛋白及其用途
CN120098931A (zh) * 2025-02-10 2025-06-06 武建强 具有杀伤和肿瘤抑制功效的tcr-t细胞及其应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5292550B2 (ja) * 2007-03-23 2013-09-18 静岡県 Ｔ細胞レセプターβ鎖遺伝子及びα鎖遺伝子
HRP20171164T1 (hr) * 2010-09-20 2017-10-20 Biontech Cell & Gene Therapies Gmbh Antigen-specifični t stanični receptori i t stanični epitopi
US9205144B2 (en) * 2011-06-03 2015-12-08 Dana-Farber Cancer Institute, Inc. Identification of conserved peptide blocks in homologous polypeptides
GB201520539D0 (en) * 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
JP2021500878A (ja) * 2017-10-12 2021-01-14 ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム 免疫療法のためのｔ細胞受容体
CN109776671B (zh) * 2017-11-14 2022-05-27 杭州康万达医药科技有限公司 分离的t细胞受体、其修饰的细胞、编码核酸、表达载体、制备方法、药物组合物和应用
EP3731876A4 (en) * 2017-12-28 2022-04-06 Gritstone bio, Inc. ANTIGEN-BINDING PROTEINS TARGETING SHARED ANTIGENS
AU2019218397A1 (en) * 2018-02-12 2020-10-01 Fred Hutchinson Cancer Center Cyclin A1 specific T cell receptors and uses thereof
AU2019275072A1 (en) * 2018-05-23 2021-01-21 Seattle Project Corp. Shared antigens
JP2021533777A (ja) * 2018-08-16 2021-12-09 ビオンテック ユーエス インコーポレイテッド Ｔ細胞受容体構築物およびその使用
GB201814362D0 (en) * 2018-09-04 2018-10-17 Treos Bio Zrt Composition and process for preparing vaccine
CN112912391A (zh) * 2018-10-25 2021-06-04 昆士兰医学研究所理事会 T细胞受体及其用途
WO2020160189A1 (en) * 2019-01-29 2020-08-06 Gritstone Oncology, Inc. Multispecific binding proteins

Similar Documents

Publication Publication Date Title
JP7270001B2 (ja) Ｍｈｃクラスｉｉ拘束性ｍａｇｅ－ａ３を認識するｔ細胞受容体
CN110785432B (zh) Tcr和肽
TWI735765B (zh) T細胞受體及其針對prame陽性癌症的免疫治療
JP7770188B2 (ja) 養子細胞療法のための標的共刺激を提供する受容体
JP2024546018A5 (enExample)
JP2024515646A5 (enExample)
JP2023534808A (ja) 養子細胞療法のための標的共刺激を提供する受容体
CN110036027A (zh) 新型t细胞受体及其免疫治疗应用
US12365717B2 (en) Specific t cell receptors against epitopes of mutant MYD88L265P protein for adoptive T cell therapy
JP2024517618A5 (enExample)
CN114502580B (zh) Mhc ii类分子及其使用方法
JP2023549765A5 (enExample)
EP3898665B1 (en) Cd22-specific t cell receptors and adoptive t cell therapy for treatment of b cell malignancies
JP2022546106A (ja) Ｅｂｖ－由来抗原に特異的なｔｃｒ構築物
Nakatsugawa et al. CD4+ and CD8+ TCRβ repertoires possess different potentials to generate extraordinarily high-avidity T cells
CN114450303B (zh) Mhc ii类分子及其使用方法
EP4091627A1 (en) Tcr constructs specific for magea4-derived epitopes
US20190359677A1 (en) Novel t cell receptors and immune therapy using the same for the treatment of cancer and infectious diseases
TWI790162B (zh) 新穎t細胞受器及使用其之免疫治療
JP2025518203A (ja) Ｍａｇｅ－ａ１特異的ｔｃｒ及びその用途
Marvel et al. The CD45RA molecule is expressed in naive murine CTL precursors but absent in memory and effector CTL
EP4491630A1 (en) T-cell receptor for acute myeloid leukemia (aml)
US12209137B2 (en) Antigen binding proteins specifically binding CT45
EP4223782A1 (en) Novel t cell receptors and immune therapy using the same for the treatment of cancer
Hess et al. Functionally divergent T lymphocyte responses induced by modification of a self-peptide from a tumor-associated antigen